RNA interference

Global RNAi Therapeutics Market Insights & Forecasts with Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

Retrieved on: 
Vendredi, mai 3, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, MicroRNA, Investment, RNA interference, Hospital, Infection, RNA, Research, Liver, HTS, Therapy, DSM-IV codes, COVID-19, Prevalence, Row

The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The global RNAi therapeutics market is expected to record a value of US$1.39 billion in 2028, progressing at a CAGR of 9.98%, over the period 2024-2028.
  • Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.
  • The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Retrieved on: 
Jeudi, mai 2, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Small RNA, AMGN, RNA interference, Risk, Partnering, Arrowhead, APOC3, Moyamoya disease, RNA, Apolipoprotein C-III, Trial, Patient, Myocardial infarction, Cardiovascular disease, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).
  • This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN).
  • Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran.
  • “Our pipeline of wholly owned or partnered TRiMTM-enabled candidates now includes three programs in Phase 3 - olpasiran, fazirsiran, and plozasiran.

Codexis Reports First Quarter 2024 Financial Results

Retrieved on: 
Jeudi, mai 2, 2024
Maple syrup urine disease, Element, Investment, SAB, RNA interference, MBBS, Alnylam Pharmaceuticals, MSUD, Ligation, Research and development, Control, Doctor of Philosophy, HCU, Administration, Roche, DNA, Senior, ECO, Marketing, MBA, Former, Advertising, GMP, Telephone, Biotechnology, McGill University, Fine chemical

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance
    REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Total revenues increased by 32% to $17.1 million for first quarter 2024 compared to $13.0 million in first quarter 2023.
  • Product revenues increased by 14% to $9.6 million for first quarter 2024 compared to $8.4 million in first quarter 2023.
  • Product gross margin was 49% for first quarter 2024 compared to 46% in first quarter 2023.

ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024

Retrieved on: 
Mardi, avril 23, 2024
Small RNA, Annual, University, Alnylam Pharmaceuticals, EDT, RNA interference, Oncology, N-Acetylgalactosamine, RNA, Doctor of Philosophy, Therapy, Shareholder, Science, ProQR, Knowledge, AGM

Shareholders that wish to attend should register as described in the notice and agenda.

Key Points: 
  • Shareholders that wish to attend should register as described in the notice and agenda.
  • As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years.
  • “We’re very pleased to nominate Martin Maier to our Board” said Daniel A. de Boer, Founder and CEO.
  • The Board will appoint James Shannon, MD, as chairperson of the Board as of the AGM.

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Vendredi, avril 19, 2024
Sale, Prospectus, RNA interference, Regulation D, Holding, Security (finance), Form, Telephone

The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.

Key Points: 
  • The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire five years from the date of issuance.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds to Bio-Path from the offering were approximately $1.2 million, before deducting the placement agent’s fees and other offering expenses payable by Bio-Path.
  • Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Jeudi, avril 18, 2024
Sale, Prospectus, RNA interference, Regulation D, Holding, Security (finance), Form, Telephone

The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
  • Immediately prior to the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company was 1,190,306.
  • Immediately following the closing of the registered direct offering and the concurrent private placement, the number of outstanding shares of common stock of the Company will be 1,565,306.
  • The gross proceeds to Bio-Path from the offering are expected to be approximately $1.2 million, before deducting the placement agent’s fees and other offering expenses payable by Bio-Path.

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
Jeudi, avril 18, 2024
FDA, University, RNA interference, Hospital, Hope, Safety, Survival, Weill Cornell Medicine, Holding, AML, Salvage therapy, Cornell University, D.O, MD Anderson Cancer Center, Patient, Clinical, Medicine, Acute myeloid leukemia, Messenger, Clinical trial, Scripps Health, BH3, Cancer, Pharmaceutical industry

By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.

Key Points: 
  • By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
  • The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
  • The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
  • Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Retrieved on: 
Lundi, avril 29, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Therapy, RNA, RNA interference, Management

Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.

Key Points: 
  • Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024.
  • Iain Ross, Silence’s Chairman of the Board, commented, “Alistair has made significant contributions to the Board and the Company over the past nine years.
  • I want to recognise and thank Alistair for his input on behalf of the Board and management over almost a decade.
  • Mr. Gray stated, “Nearly 10 years after joining the Silence Board and at age 75, I feel the time is right to retire as a director.

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Retrieved on: 
Jeudi, avril 11, 2024
University, Agriculture, SAB, RNA interference, Biochemistry, Research, Central Waqf Council, State university system, Business administration, RNA, Danisco, Doctor of Philosophy, Cell, Molecular biology, Genencor, Chemical engineering, Buffalo, Therapy, Senior, Cobalt, Patient, Cobalt Technologies, Bachelor, ECO, Codexis, Green-light, MBA, Biotechnology, Management

REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB).

Key Points: 
  • REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB).
  • Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agriculture and pharmaceutical applications.
  • Her deep biotechnology experience includes leadership roles across fermentation-based commercial manufacturing, process development, plant operations and global supply chain management.
  • “We are honored to have Carole join Codexis as the newest member of our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Retrieved on: 
Mercredi, avril 24, 2024
Science, Research, Pharmaceutical, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, Kidney disease, IgA nephropathy, RNA interference, Arrowhead, Kidney, CFB, RNA, Patient, Liver, System, Translational medicine, Discovery, MBA, Complement factor B, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.
  • James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “In preclinical studies, ARO-CFB achieved deep and durable reductions in liver production of complement factor B, which is involved in alternative complement pathway activation and associated with pathogenesis of diseases involving complement activation.
  • ARO-CFB is our second clinical program designed to address diseases associated with activation of the complement pathway, the first being ARO-C3, our Phase 1 program targeting complement component 3.
  • ARO-CFB is being developed as a potential treatment for complement mediated kidney diseases such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease.